aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
BridgeBio Pharma, based in Palo Alto, focuses on developing transformative medicines for genetic diseases and cancers with clear genetic drivers. The company aims to merge finance and science to expedite drug development, providing innovative solutions to patients worldwide. Their platform emphasizes rapid scientific discovery and development, ensuring that breakthroughs quickly translate into patient treatments.
BridgeBio Pharma has made significant strides in the biotech industry, with a robust pipeline of potential therapies targeting various genetic conditions. Their rigorous approach to science and commitment to patient outcomes have positioned them as a key player in the field. The company's impact is evident in its ongoing efforts to bring new, effective treatments to market, improving the lives of patients globally.
Operating Status
Active
Ownership Type(s)
Public
Main Product(s)
Genetic Medicines
Technology
Biotech
Tags
Healthtech
Model Types
Platform, Software
Revenue Type(s)
Recurring
Customer Type(s)
Consumers, Enterprise
Geographic Exposure
Global
When was BridgeBio Pharma founded?
BridgeBio Pharma was founded in 2015.
Where is BridgeBio Pharma's headquarters located?
BridgeBio Pharma's headquarters is located in Palo Alto, CA, US.
When was BridgeBio Pharma's last funding round?
BridgeBio Pharma's most recent funding round was for $1.3B (USD) in January 2024.
How many employees does BridgeBio Pharma have?
BridgeBio Pharma has 392 employees as of Feb 6, 2024.
How much has BridgeBio Pharma raised to-date?
As of July 05, 2023, BridgeBio Pharma has raised a total of $3.6B (USD) since Jan 18, 2024.
Add Comparison
Total Raised to Date
$3.6B
USD
Last Update Jan 18, 2024
Last Deal Details
$1.3B
USD
Jan 18, 2024
Post Ipo Debt
Total Employees Over Time
392
As of Feb 2024
BridgeBio Pharma Address
165 University Ave
Palo Alto,
California
94301
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts